Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?

BACKGROUND: To account for interindividual variability in the pharmacokinetics (PK) of factor concentrates, PK‐guided dosing is increasingly implemented in haemophilia patients. Calculations are based on provided label potency, but legislation allows a potency difference of ±20% between label and ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Goedhart, Tine M.H.J., Bukkems, Laura H., van Moort, Iris, Spence, Colin C., Zwaan, Michel C., de Maat, Moniek P.M., Mathôt, Ron A.A., Cnossen, Marjon H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546314/
https://www.ncbi.nlm.nih.gov/pubmed/35526235
http://dx.doi.org/10.1111/hae.14575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546314/
https://www.ncbi.nlm.nih.gov/pubmed/35526235
http://dx.doi.org/10.1111/hae.14575

Ejemplares similares